Orthopaedic Meeting | #Orthocell is proud to be an Exhibition Sponsor at the AOA WA Annual Scientific Meeting, 29–30 August 2025 at the Ritz-Carlton in Perth. Visit our team to learn more about our market-leading medical devices.

Orthocell is on the road in the US this September, showcasing Remplir™, our FDA-cleared nerve repair device, at four leading US meetings: Disaster Plasty, Duke Nerve Course, Balance Health Summit, and NESPS. $OCC #Orthocell #Remplir #NerveRepair #RegenerativeMedicine #Innovation

Orthocell has today published its Annual Report for FY25. Click here to read the full report: bit.ly/OCC-FY25-Annua… $OCC #Orthocell #innovation #regenerativemedicine #global #nerve #nerverepair #UnitedStates #healthcare

$OCC | #Orthocell has today released interim results from a new Remplir™ Real World Evidence study, demonstrating an overall treatment success rate of 81.1% following nerve repair procedures. Read the ASX release: bit.ly/OCC_RWE_Study #nerverepair #realworldevidence #USmarket

Orthocell is proud to be attending the 80th Annual Meeting of the American Society for Surgery of the Hand (ASSH) next month in Canada. This event brings together the global hand surgery community to share the latest research, clinical advances and innovations shaping the field.

#Orthocell has identified a promising new application for its flagship Remplir™ nerve repair, supporting nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP) during prostate cancer surgery. Read the ASX release: bit.ly/OCC_Remplir_Pr… $OCC #medicaldevice #nerverepair

Interview | This week #Orthocell Chairman John Van Der Wielen spoke with Proactive’s Fouad Haidar about Remplir’s promising new application in supporting nerve-sparing robotic prostate cancer surgeries Watch the full interview here: youtu.be/wGkPhHbtU10?si… $OCC #nerverepair

#Orthocell is featured in this Stockhead Special Report, published in The Australian, outlining how Australian urologists are now using Orthocell’s flagship nerve repair product Remplir during #prostatecancer surgery. Take a look: bit.ly/OCC_TheAustral… $OCC #nerverepair

Orthocell was featured in an article by biotech journalist Tim Boreham titled “Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market.” It’s worth a read: bit.ly/4nzo8Iy $OCC #Orthocell #innovation #nerverepair @Stockhead

$OCC | #Orthocell delivers record quarterly revenue of $3.0m for the September quarter – the 6th consecutive record. Read today’s ASX release: bit.ly/3ILWgl2 #medtech #regenerativemedicine #remplir #growth

INTERVIEW | Orthocell Chairman, John Van Der Wielen, recently discussed the Company’s outstanding revenue on Proactive. Take a look: bit.ly/4h45y90 $OCC #Orthocell #nerverepair #Remplir #revenue #growth Proactive

$OCC | Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress. Read the ASX release: bit.ly/43dFZwd $ #nerverepair #innovation #regenerativemedicine #growth #ASX

Orthocell Founder & CEO Paul Anderson has been named a National Finalist in the EY Entrepreneur of the Year Awards, representing WA in the Technology category. His vision continues to shape Australian innovation on the world stage. $OCC #Orthocell #EOY #EOYAustralia #25YearsofEOY

Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.  🔗Read the ASX release: bit.ly/4nYtvRJ $OCC #Orthocell #regenerativemedicine #innovation #capitalraise #invest #nerverepair #global

Orthocell has signed an MOU to increase its equity stake in Marine Biomedical for a consideration of AU$1.0 million, securing exclusive first right of refusal over global distribution rights their bone substitute product, PearlBone™. Read the ASX release: bit.ly/4nfX7Jc

Great to connect with the surgical community at #ASSH2025 in Vancouver to discuss Remplir™ and the evolving landscape of peripheral nerve repair. Thank you to everyone who visited our booth or shared clinical insights – your expertise continues to shape surgical practice.